罗氏收购Lumora公司的核酸纯化技术

  为了建立公司自身的技术组合，罗氏公司今日宣布了一项最终的资产购买协议，即购买Lumora公司的样品制备技术（核酸纯化技术）用于测序。
  罗氏目前正在购买Lumora公司与热洗脱技术相关的产品用于进行核酸的纯化，该技术可以被用于进行多种类型样本的处理，比如福尔马林-石蜡包埋的肿瘤样本，而且罗氏表示，它们还将计划整合该技术使其成为测序工作流程的解决方案。
  Lumora公司的这项技术可以在短短几分钟内自动化地从福尔马林-石蜡包埋的组织中分离出核酸，而其它传统的技术则需要几个小时；罗氏公司表示，该技术还可以对全血、粪便物、唾液及腔内拭纸进行处理提取核酸。
  Lumora的CEO Laurence Tisi在一份声明中将核酸抽提技术定义为测序工作流程的重要一环，而热洗脱技术可以明显简化提取的过程，而且实现了最简单的自动化操作，该项技术将帮助罗氏在完全整合的测序设备上奠定坚实唯一的位置。目前针对该项收购协议的金融和其他交易条款并没有被披露。
  这笔交易将会是罗氏建立自己技术能力的跨越性的一步，上周罗氏公司已经宣布收购分子生物学酶类公司Kapa Biosystems，本月早些时候罗氏已经同意以4.25亿美元购买临床诊断公司GeneWeave；今年春天罗氏已经收购了CAPP Medical公司，该公司主要致力于基于对循环肿瘤DNA进行分析的新一代测序技术来进行癌症筛查和癌症监测。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的原文摘要：

Roche Buys Lumora's Nucleic Acid Purification Technology

In yet another deal to build up its technology portfolio, Roche today announced a definitive asset purchase agreement for Lumora's sample prep technology for sequencing.

Roche is purchasing Lumora's products associated with its heat elution technology for nucleic acid purification. The technology can be used for multiple sample types, such as formalin-fixed paraffin-embedded tumor samples, and Roche said that it plans to integrate the technology into its sequencing workflow solution.

The technology is for research use only.

Lumora's technology enables automated nucleic acid isolation from FFPE in minutes, as opposed to hours with other technologies, Roche said. The technology can also be used with whole blood, fecal matter, sputum, and buccal swabs.

In a statement, Lumora CEO Laurence Tisi called nucleic acid extraction an "important bottleneck in [the] sequencing workflow. Heat elution technology significantly simplifies extraction and is simple to automate. The acquisition of this technology may offer Roche a unique position in fully integrated sequencing devices."

Financial and other terms of the deal were not disclosed.

The deal is the latest in a recent string of transactions by Roche to build up its technology capabilities. Last week, it announced an agreement to buy molecular biology enzyme firm Kapa Biosystems. Earlier in the month, Roche also agreed to buy clinical diagnostics firm GeneWeave for as much as $425 million; and in the spring, it acquired CAPP Medical, which specializes in next-generation sequencing-based analysis of circulating tumor DNA for cancer screening and monitoring.